Hem › Triplenegativ bröstcancer › New York › New York City
Kliniska studier för Triplenegativ bröstcancer i New York City, NY
31 studier för Triplenegativ bröstcancer söker deltagare vid platser i och runt New York City (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RekryterarFas 1
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- Icahn School of Medicine at Mount Sinai, New York
- och 2 fler
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekryterarFas 1/2
- Columbia University Medical Center, New York
- Memorial Sloan Kettering, New York
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
RekryterarFas 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Study of AVZO-021 in Patients With Advanced Solid Tumors
RekryterarFas 1/2
- Avenzo Therapeutics Recruiting Site, New York
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RekryterarObservationsstudie
- NYU Langone Medical Center, New York
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
RekryterarFas 3
- Laura and Isaac Perlmutter Cancer Center ( Site 0003), New York
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
RekryterarFas 3
- The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0135), New York
- Icahn School of Medicine at Mount Sinai ( Site 0123), New York
- Memorial Sloan Kettering Cancer Center ( Site 0067), New York
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RekryterarFas 1
- Memorial Sloan Kettering Cancer Center Head Neck Services, New York
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
RekryterarFas 1
- Icahn School of Medicine at Mt. Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer
RekryterarFas 1
- Memorial Sloan Kettering Cancer Center (All protocol activites), New York
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
RekryterarFas 1/2
- Mount Sinai, New York
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
RekryterarFas 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
RekryterarFas 2
- NYP/Weill Cornell Medical Center, New York
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RekryterarFas 3
- Laura and Isaac Perlmutter Cancer Canter, New York
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
RekryterarFas 1
- New York University (NYU) Clinical Cancer Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer
RekryterarFas 2
- Memorial Sloan-Kettering Cancer Center (All Protocol Activities), New York
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
RekryterarFas 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
RekryterarFas 2/3
- Memorial Sloan Kettering Cancer Center, New York
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
RekryterarFas 1
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
- Memorial Sloan Kettering Cancer Center 53rd street., New York
- Memorial Sloan Kettering Cancer Center - Main Campus, New York
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
RekryterarFas 1/2
- New York University Langone Health, New York
- ICHAN School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of LY4175408 in Participants With Advanced Cancer
RekryterarFas 1
- Columbia University, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
RekryterarFas 1
- New York Medicine-New York-Presbyterian Hospital, New York
- Montefiore Medical Center - Montefiore Hospital, New York
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
RekryterarFas 1/2
- Memorial Sloan Kettering Cancer Center, New York
Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer
RekryterarTidig fas 1
- Mount Sinai Health System, New York
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RekryterarFas 2
- Laura and Isaac Perlmutter Cancer Center / NYU Langone Health, New York
- Columbia University Medical Center, New York
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
RekryterarFas 1/2
- NYU Langone perimutter Cancer Center, New York
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
RekryterarFas 1
- Memorial Sloan Kettering Cancer Center, New York
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
RekryterarFas 2
- Memorial Sloan Kettering Cancer Center, New York
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
RekryterarFas 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
RekryterarFas 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RekryterarFas 1/2
- NYU Langone Health, New York
Triplenegativ bröstcancer-studier i andra städer
- Houston, TX42 studier
- Nashville, TN28 studier
- Los Angeles, CA27 studier
- Boston, MA26 studier
- San Antonio, TX23 studier
- St. Louis, MO21 studier
- Arlington, VA20 studier
- Atlanta, GA20 studier
- Dallas, TX18 studier
- Chicago, IL16 studier
- Columbus, OH16 studier
- Grand Rapids, MI15 studier
Andra studier i New York City
- Bröstcancer136 studier
- Icke-småcellig lungcancer121 studier
- Cancer (alla typer)109 studier
- Prostatacancer103 studier
- Metastaserande cancer93 studier
- Kolorektal cancer78 studier
- Äggstockscancer69 studier
- Lungcancer60 studier
- Multipelt myelom60 studier
- Bukspottkörtelcancer60 studier
- Endometriecancer52 studier
- Akut myeloid leukemi51 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.